Tacrolimus-Associated Thrombotic Microangiopathy Presenting with Ischemic Colitis After Kidney Transplantation: A Case Report
Abstract
Calcineurin inhibitors (CNIs) are a significant component of the immunosuppressive regimen after kidney transplantation. By inhibiting cytokine gene transcription, CNIs suppress T cell and T cell-dependent B cell activation. Tacrolimus is preferred in most patients undergoing kidney transplantation. Thrombotic microangiopathy (TMA) is a severe but rare complication of CNIs therapy. TMA defines a specific pathologic lesion of arterioles and capillaries that leads to microvascular thrombosis. A 45-year-old male underwent kidney transplantation five months ago due to autosomal dominant polycystic kidney disease (ADPKD). His triple-maintenance immunosuppressive therapy includes tacrolimus. Abdominal pain and bloody diarrhea occurred in the fifth month of posttransplant. The edematous and erythematous mucosa of the ascending colon was detected on the colonoscopy. The foci of microthrombi inside the vessel lumen in the lamina propria were shown biopsy. The thrombosis or occlusion was excluded with computerized tomography (CT) angiography in abdominal vessels. The fragmented red blood cells and moderate thrombocytopenia were detected on the peripheral blood smear. Eventually, TMA diagnosis was established through laboratory and histological findings. Tacrolimus was suspected as the trigger of the pathological process and promptly switched to the everolimus. Afterward, laboratory abnormalities and clinical symptoms were improved. In this case, we intend to emphasize drug-associated TMA and atypical presentations, such as colonic microvasculature involvement.
Keywords
kidney transplantation , tacrolimus , thrombotic microangiopathy , ischemic colitis
Kaynakça
- Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can’t live without. The Journal of Immunology 2013; 191(12):5785-91.
- Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331(7520):810.
- George JN, Nester CM. Syndromes of Thrombotic Microangiopathy. New England Journal of Medicine 2014; 371(7):654-66.
- Toriu N, Sekine A, Mizuno H, Hasegawa E, Yamanouchi M, Hiramatsu R, et al. Renal-limited thrombotic microangiopathy due to bevacizumab therapy for metastatic colorectal cancer: a case report. Case Reports in Oncology 2019; 12(2):391-400.
- Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clinical Journal of the American Society of Nephrology 2018; 13(2):300-17.
- Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Seminars in Thrombosis and Hemostasis 2014; 40(4):444-64.
- Kathula SK, Koduri J, Mall S, Chang JC. A case report of total abdominal hysterectomy resulting in acute thrombotic thrombocytopenic purpura with pancreatitis and hepatitis: complete resolution with plasma exchange therapy. Therapeutic Apheresis and Dialysis 2003; 7(3):373-4.
- Smirnova T, Kozlovskaya N, Sheludchenko V. Ocular manifestations of primary thrombotic microangiopathy. Vestnik Oftalmologii 2021; 137(5):138-44.
- Dubois A, Lyonnet P, Cohendy R, Said HO, Branger B, Raffanel C, et al. Ischemic colitis as a manifestation of Moschkowitz's syndrome. In: Annales de Gastroenterologie et d'Hepatologie: 1989; 1989: 19.
- See JR, Sabagh T, Barde CJ. Thrombotic thrombocytopenic purpura: a case presenting with acute ischemic colitis. Case Reports in Hematology 2013; 2013:592930.